Detailed Research on Wounds - Pipeline Review, H1 2017
Wounds - Pipeline Review, H1 2017 is a new market research publication announced by Reportstack. This report provides an overview of the Wounds (Dermatology) pipeline landscape.
Wound is a breakdown in the protective function of the skin (the loss of continuity of epithelium) with or without loss of underlying connective tissue (i.e. muscle, bone, nerves) following injury to the skin or underlying tissues/ organs caused by surgery, a blow, a cut, chemicals, heat/ cold, friction/ shear force, pressure or as a result of disease, such as leg ulcers or carcinomas. Signs and symptoms include redness or red streaks on the skin surrounding the wound, increased swelling to tenderness at the wound site, pus-like drainage or a foul smell from the wound and body chills or fever.
Complete report available @ Wounds - Pipeline Review, H1 2017
Report Highlights
The Pharmaceutical and Healthcare latest pipeline guide Wounds - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Wounds (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Wounds (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Wounds and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 5, 1, 58, 8 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 12 and 7 molecules, respectively.
Wounds (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Wounds (Dermatology).
- The pipeline guide reviews pipeline therapeutics for Wounds (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Wounds (Dermatology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Wounds (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Wounds (Dermatology)
- The pipeline guide reviews pipeline therapeutics for Wounds (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Wounds (Dermatology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Wounds (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Wounds (Dermatology)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Wounds (Dermatology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Wounds (Dermatology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Wounds (Dermatology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Wounds (Dermatology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned
AlgiPharma AS Alliance Pharma Plc AmpliPhi Biosciences Corp AndroScience Corp Anterogen Co Ltd Aridis Pharmaceuticals LLC Beech Tree Labs Inc Bio3 Research Srl Biotec Pharmacon ASA Blueberry Therapeutics Ltd Cellphire Inc Chiesi Farmaceutici SpA CorMedix Inc Dermala Inc Destiny Pharma Ltd Escape Therapeutics Inc EyeGene Inc FibroGen Inc Foresee Pharmaceuticals LLC Gene Signal International SA GlaxoSmithKline Plc IC-MedTech Inc Living Cell Technologies Ltd Madam Therapeutics BV miRagen Therapeutics Inc NatureWise Biotech & Medicals Corp Novan Inc Octapharma AG Omeros Corp Osiris Therapeutics Inc Pacific Northwest Biotechnology LLC ProMetic Life Sciences Inc RMB-Research GmbH RXi Pharmaceuticals Corp SomaGenics Inc Stratatech Corp Synedgen Inc Thesan Pharmaceuticals Inc Topadur Pharma AG Traverse Biosciences Inc Tumorend LLC Vascular BioSciences viDA Therapeutics Inc
Contact:
Debora White
Manager - Marketing
Ph: +1-888-789-6604
ReportstackMarket Research
###
posted by Reportstack @ 07:17
0 Comments
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home